Dr. ABHISHEK

Dr. PRABHAKAR SINGH

Abstract

Linezolid(Lz) is used in XDRTB which is known to cause optic neuropathy(ON). It’s important to report the ocular safety,side effect and prevalence of ON in XDR-TB. Patients with complaints of diminution of vision secondary to Lz were evaluated.30 patients analysed. Mean age at presentation-30.8±9.9 years. 20 male,10 female. Average duration of Lz use was 9.0±3.9 months,dosage 600mg once daily. Presenting vision ranged from 6/18 to CF.CV impaired in all. Optic disc finding ranged from normal to total pale.VEP depressed in 22 and flat in 8.On HVF centrocaecal scotoma found in 36%,non specific field defects in 36%.OCT RNFL showed increased thickness in 40%,high normal in 33% and reduced thickness in 27%.Patients presenting early within 3 weeks regained vision while those presenting late did not recover.Prevalence of ON-9% and occurred after use beyond 4-6 months.The earlier the patient presented better the chances of recovery.Toxicity correlated to duration of treatment,rather than dose.

Full Text